You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

September 4, 2018

Practical Law Life Sciences Global Guide: Pharmaceutical IP and Competition Law in Thailand

Practical Law

The 2018 edition of Thomson Reuters’ Practical Law Life Sciences Global Guide  has been released, with a chapter on Pharmaceutical Intellectual Property and Competition Law in Thailand penned by legal practitioners from Tilleke & Gibbins.

The guide is a Q&A-style overview of the regulatory frameworks of the life sciences industries across multiple jurisdictions worldwide, with this chapter addressing the following issues as they relate to Thailand:

  • Pharmaceutical patent legislation and scope of protection
  • Patent application process, duration of protection, and revocation
  • Patent infringement, claims, and remedies
  • Non-patent barriers to competition for pharmaceutical protection
  • Pharmaceutical trademark legislation and scope of protection
  • Trademark application process, duration of protection, and revocation
  • Trademark infringement, claims, and remedies
  • Regulatory powers and enforcement against pharmaceutical counterfeiting
  • Competition law framework and implications for the pharmaceutical sector
  • Competition issues related to licensing of pharmaceutical technology and patents, and market entry of generic products
  • Market dominance issues in the pharmaceutical sector
  • Parallel imports
  • Foreign patent and trademark licenses, and payment of royalties

Practical Law, produced by Thomson Reuters, is the world’s leading legal know-how resource for business lawyers, publishing a huge range of guides covering hundreds of jurisdictions and practice areas. Tilleke & Gibbins also drafted a chapter on Medicinal Product Regulation and Product Liability in Thailand for the 2018 edition of the guide.

RELATED INSIGHTS​ 

October 25, 2016
On February 4, 2016, Vietnam and 11 other countries signed the Trans-Pacific Partnership (TPP). The TPP includes Australia, Brunei, Canada, Chile, Japan, Malaysia, Mexico, New Zealand, Peru, the United States, Vietnam, and Singapore—countries which represent 36 percent of global GDP and more than 25 percent of world trade.
October 25, 2016
On May 15, 2016, shortly before the new Law on Pharmacy was adopted, the Vietnamese government issued Decree No. 36/2016/ND-CP on the management of medical devices (Decree 36). This decree took effect on July 1, bringing medical devices under uniform management. Previously, there were two separate systems of legislation—one for medical devices manufactured domestically and the other for imported medical devices.
October 3, 2016
Biologics are composed of complex, large molecules, as opposed to the small molecules that make up conventional chemically derived drugs. Because of the complex nature of biologics, clinical trials and data collections are expensive to produce and require a heightened level of data exclusivity protection beyond those of a patent to incentivize biologic producers to continue research on new biologics.
October 3, 2016
In 2002, the Thai government initiated a universal healthcare scheme to bring equitable healthcare access to the general public. Under the scheme, hospitals receive per capita funding based on 47 million people. At the outset, per capita funding was approximately USD 38 per person. Now, it is USD 83. Although per capita funding has more than doubled, the current figure is still low. This budget constraint has led the Thai government to favor generic companies, as opposed to originator companies.Definition of Biological Product